Sera Prognostics said this week that it has exceeded enrollment of 4,000 subjects in its Proteomic Assessment of Preterm Risk clinical study supporting the validation of its proteomic test for predicting risk of preterm birth.

The enrollment numbers mark a milestone in the company's plan to commercially launch the test by the end of this year. They also have a broader significance for the proteomics field as an indication of mass spec's viability as a platform for high-throughput clinical validation and implementation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.